Literature DB >> 17666649

Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor.

Mary Pat Hardman1, Juan J Roman, Alexander F Burnett, Alessandro D Santin.   

Abstract

BACKGROUND: Metastatic and disseminated uterine leiomyosarcoma has limited chemotherapeutic options. CASE: A 45-year-old nulligravida was originally diagnosed with a primary uterine leiomyosarcoma and treated with a total abdominal hysterectomy, followed by six courses of adjuvant platinum and doxorubicin chemotherapy. Three years later she developed multiple metastatic tumor nodules in the lungs. Because of the estrogen receptor positivity of the leiomyosarcoma by immunohistochemistry, she was treated with 1 mg of anastrozole daily. Progressive tumor regression was demonstrated by serial imaging in all metastatic lung tumor deposits, with an objective response lasting at least 12 months.
CONCLUSION: Uterine leiomyosarcoma metastatic to the lungs regressed with the use of the anastrozole aromatase inhibitor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17666649     DOI: 10.1097/01.AOG.0000267533.56546.c2

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  9 in total

1.  Leiomyosarcoma: Principles of management.

Authors:  Juan Martin-Liberal
Journal:  Intractable Rare Dis Res       Date:  2013-11

Review 2.  Current management of uterine sarcomas.

Authors:  Elena García-Martínez; Lucas Egea Prefasi; Jesús García-Donas; Pedro Pablo Escolar-Pérez; Francisco Pastor; Antonio González-Martín
Journal:  Clin Transl Oncol       Date:  2011-05       Impact factor: 3.405

3.  Contemporary management and classification of hepatic leiomyosarcoma.

Authors:  Mazin O Hamed; Keith J Roberts; William Merchant; J Peter A Lodge
Journal:  HPB (Oxford)       Date:  2014-11-24       Impact factor: 3.647

4.  Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.

Authors:  Roisin O'Cearbhaill; Qin Zhou; Alexia Iasonos; Robert A Soslow; Mario M Leitao; Carol Aghajanian; Martee L Hensley
Journal:  Gynecol Oncol       Date:  2009-11-24       Impact factor: 5.482

5.  Potential benefit of hormonal therapy for non-uterine soft tissue sarcoma (STS) - a case report and literature review.

Authors:  Li Li; Isaiah P Schuster; Robin Jacob; Kenneth H Hupart; Vladimir Gotlieb
Journal:  Springerplus       Date:  2013-10-17

Review 6.  New Insights into Hormonal Therapies in Uterine Sarcomas.

Authors:  Elena Maccaroni; Valentina Lunerti; Veronica Agostinelli; Riccardo Giampieri; Laura Zepponi; Alessandra Pagliacci; Rossana Berardi
Journal:  Cancers (Basel)       Date:  2022-02-12       Impact factor: 6.639

Review 7.  Uterine fibroids: current perspectives.

Authors:  Aamir T Khan; Manjeet Shehmar; Janesh K Gupta
Journal:  Int J Womens Health       Date:  2014-01-29

8.  Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors.

Authors:  Eirini Thanopoulou; Khin Thway; Komel Khabra; Ian Judson
Journal:  Clin Sarcoma Res       Date:  2014-06-26

9.  Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma.

Authors:  My Linh Thibodeau; Caralyn Reisle; Eric Zhao; Lee Ann Martin; Yazeed Alwelaie; Karen L Mungall; Carolyn Ch'ng; Ruth Thomas; Tony Ng; Stephen Yip; Howard J Lim; Sophie Sun; Sean S Young; Aly Karsan; Yongjun Zhao; Andrew J Mungall; Richard A Moore; Daniel J Renouf; Karen Gelmon; Yussanne P Ma; Malcolm Hayes; Janessa Laskin; Marco A Marra; Kasmintan A Schrader; Steven J M Jones
Journal:  Cold Spring Harb Mol Case Stud       Date:  2017-09-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.